Research from the last two decades showing that the BCR is a major driver in CLL has profoundly transformed our therapeutic landscape with the introduction of BCR pathway antagonists in essentially all treatment lines. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.